How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?

Area of Science:

• Hematologic Malignancies
• Geriatric Oncology
• Pharmacology

Background:

• Chronic lymphocytic leukemia (CLL) frequently affects elderly patients, who often present with multiple comorbid medical conditions.
• Despite competing health issues, CLL or its complications remain the primary cause of mortality in this demographic.
• Management of CLL in the elderly necessitates careful consideration of comorbidities and their impact on treatment decisions.

Purpose of the Study:

• To review current treatment strategies for elderly patients diagnosed with chronic lymphocytic leukemia (CLL).
• To discuss the evolving role of targeted agents in managing CLL in older adults.
• To highlight the importance of individualized treatment approaches considering patient fitness and comorbidities.

Main Methods:

• Review of recent clinical trials and literature focusing on CLL treatment in elderly populations.
• Assessment of various comorbidity indices (e.g., Charlson, CIRS, CLL-CI) in treatment planning.
• Analysis of efficacy and safety data for novel targeted agents in CLL management.

Main Results:

• The treatment paradigm for CLL has shifted from traditional chemoimmunotherapy to targeted agents, demonstrating improved progression-free survival (PFS).
• Clinical trials show efficacy of agents like ibrutinib, acalabrutinib, zanubrutinib, venetoclax, idelalisib, and duvelisib in elderly CLL patients.
• Further research is required to fully understand adverse event profiles and drug-drug interactions associated with these targeted therapies.

Conclusions:

• Targeted agents have significantly improved outcomes for elderly patients with CLL.
• Treatment decisions must be individualized, considering patient-specific fitness, comorbidities, and concomitant medications.
• Ongoing research is essential to establish optimal treatment practices and manage potential toxicities in this vulnerable population.